In summary, our results elucidate how MDS/MPN CBL mutants or inactivated CBL elicit gain-of-function properties by deregulating CBL–CIN85 signaling and provide evidence that targeting the RTK–CBL–CIN85 axis could inhibit oncogenesis. The gene discussed is SH3KBP1; the disease is myelodysplastic syndrome.